Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences Inc (INBX)
NASDAQ:INBX
RESEARCH TOOLSreports
Total Valuation
Inhibrx Biosciences Inc has a market cap or net worth of $186.16M. The enterprise value is $17.22M.
Market Cap$186.16M
Enterprise Value$17.22M
Share Statistics
Inhibrx Biosciences Inc has 14,475,904 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,475,904
Owned by Insiders26.74%
Owned by Institutions47.00%
Financial Efficiency
Inhibrx Biosciences Inc’s return on equity (ROE) is 12.63 and return on invested capital (ROIC) is -234.02%.
Return on Equity (ROE)12.63
Return on Assets (ROA)9.34
Return on Invested Capital (ROIC)-234.02%
Return on Capital Employed (ROCE)-2.37
Revenue Per Employee1.28K
Profits Per Employee10.82M
Employee Count156
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibrx Biosciences Inc is 0.13. Inhibrx Biosciences Inc’s PEG ratio is -0.08.
PE Ratio0.13
PS Ratio0.00
PB Ratio1.21
Price to Fair Value1.67
Price to FCF-0.82
Price to Operating Cash Flow-0.83
PEG Ratio-0.08
Income Statement
In the last 12 months, Inhibrx Biosciences Inc had revenue of 200.00K and earned 1.69B in profits. Earnings per share was 114.01.
Revenue200.00K
Gross Profit-2.08M
Operating Income-331.45M
Pretax Income1.69B
Net Income1.69B
EBITDA1.70B
Earnings Per Share (EPS)114.01
Cash Flow
In the last 12 months, operating cash flow was -194.41M and capital expenditures -2.60M, giving a free cash flow of -197.01M billion.
Operating Cash Flow-194.41M
Free Cash Flow-197.01M
Free Cash Flow per Share-13.61
Dividends & Yields
Inhibrx Biosciences Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change-7.61%
50-Day Moving Average12.63
200-Day Moving Average13.99
Relative Strength Index (RSI)55.86
Average Volume (3m)98.28K
Important Dates
Inhibrx Biosciences Inc upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Inhibrx Biosciences Inc as a current ratio of 3.94, with Debt / Equity ratio of 6.02%
Current Ratio3.94
Quick Ratio3.94
Debt to Market Cap<0.01
Net Debt to EBITDA-0.08
Interest Coverage Ratio-24.57
Taxes
In the past 12 months, Inhibrx Biosciences Inc has paid 2.00K in taxes.
Income Tax2.00K
Effective Tax Rate<0.01
Enterprise Valuation
Inhibrx Biosciences Inc EV to EBITDA ratio is 0.05, with an EV/FCF ratio of -0.40.
EV to Sales391.90
EV to EBITDA0.05
EV to Free Cash Flow-0.40
EV to Operating Cash Flow-0.40
Balance Sheet
Inhibrx Biosciences Inc has $152.60M in cash and marketable securities with $8.05M in debt, giving a net cash position of -$144.55M billion.
Cash & Marketable Securities$152.60M
Total Debt$8.05M
Net Cash-$144.55M
Net Cash Per Share-$9.99
Tangible Book Value Per Share$9.23
Margins
Gross margin is -662.00%, with operating margin of -165724.00%, and net profit margin of 843786.00%.
Gross Margin-662.00%
Operating Margin-165724.00%
Pretax Margin843787.00%
Net Profit Margin843786.00%
EBITDA Margin851675.00%
EBIT Margin850532.50%
Analyst Forecast
The average price target for Inhibrx Biosciences Inc is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―